Skip to main content

Click here for an archive of Cramer's "Mad Money" Recaps.

Rewarding Behavior

"There's a bull market in insanity," said Jim Cramer on his "Mad Money" TV show Thursday, and

Psychiatric Solutions


is the way to play it.

Treatments for mental illness have improved over the years, and at the same time, demand has grown, said Cramer.

As awareness has increased, the stigma that used to be associated with mental illness has faded.

Psych Solutions, a psychiatric hospital company, is a "safe, secular growth stock" that can't be hurt by a slowdown in the economy, said Cramer.

The company is growing organically, and through "disciplined" acquisitions -- its most recent being the mental health division of



Cramer said that Psych Solutions recently had a stock offering at $50, so "don't pay too much." But, the bottom line is, "if you want to catch the bull market in mental health -- and it is a huge bull market -- buy some Psychiatric Solutions."

A caller wanted to know which pharmaceutical companies are best positioned in the market for antipsychotic drugs.

Cramer mentioned

Eli Lilly

(LLY) - Get Eli Lilly and Company Report

Scroll to Continue

TheStreet Recommends

, along with

Bristol-Myers Squibb

(BMY) - Get Bristol-Myers Squibb Company Report

and its drug Abilify, adding that he would "do a 'mon back* on Bristol."

Cramer also talked about



and its implantable drug delivery system for epilepsy, which he said might someday be used for the delivery of antipsychotic drugs, as well.

Pay Attention to Shire

Adult use of attention-deficit disorder (ADD) medications more than doubled from 2000 to 2004, said Cramer, and pediatric use has grown 70%.

In fact, he said, the use of ADD medications has grown faster than any other kind of drug except for those for rheumatoid arthritis.

The play Cramer likes from these data is

Shire Pharmaceuticals Group

( SHPGY). Shire makes Adderall XR, the "No. 1 drug" for ADD and attention-deficit-hyperactivity disorder (ADHD).

We have every reason to believe the strong growth in these drugs will continue, said Cramer. But, Shire is a "high risk" play because it is being sued by

Barr Pharmaceuticals

( BRL) because Barr wants to make generic Adderall and Adderall XR.

"It's possible they settle with Barr and come to some kind of arrangement. It's possible they don't settle; it's possible they lose," he said.

No matter what, Adderall comes off patent in mid-2006. "So, if you want to bet on the success of Adderall, keep a short time horizon," said Cramer.

It's a "short-term bet on higher-than-expected sales growth of Adderall and Adderall XR in the next two or three quarters.

"When Adderall goes off patent, this play is mostly over," although Shire does have some promising products in the pipeline, Cramer noted.

But, "that's a different bet than the one we just made on Adderall. It's a more speculative, more risky investment."

Cramer also mentioned


( CEPH), which has a new ADD drug expected to come out in the second quarter of 2006.

Cramer thinks it could be a $500 million drug -- double what the market expects.

He recommended Shire as a play for the next six months and Cephalon as a play six months from now.

Hokus Pocus

Cramer was bullish on

Hoku Scientific

( HOKU) as a "Mad Money" investment. Hoku makes "proprietary" membranes for fuel cells and is profitable, he said.

And, with oil so high, fuel cells actually make economic sense, he said.

But, Cramer cautioned that "nobody really knows anything" about the stock. So, be careful, and "don't pay much above the closing price." Hoku closed Thursday's regular session at $7.60.


(CELG) - Get Celgene Corporation Report

CFO Bob Hugin joined Cramer by telephone as a guest on the show. Cramer asked the CFO if his company was finally getting the respect it deserved.

Hugin said he didn't know, but said the company's prospects "never looked better."

Cramer wanted to know when Celgene's myeloma drug Revlimid, which was recommended for approval Wednesday by a Food and Drug Administration advisory panel, would actually reach the market.

Hugin said the FDA had set Oct. 7 as the date for a final ruling. "I only know of one case where the FDA has ever gone against the advisory committee," Hugin said.

When Revlimid is approved, the company will begin marketing the drug to doctors "very quickly thereafter," he said.

Cramer summed up the interview by saying, "this is a real company" that's making money, which now has the "biggest product in its history.

"While this stock is up 25 points, it's still not too late to do a 'mon back."

Lightning Round


Cramer was bullish on

Toyota Motor

(TM) - Get Toyota Motor Corporation Report


Duke Energy

(DUK) - Get Duke Energy Corporation (Holding Company) Report


PNM Resources

(PNM) - Get PNM Resources Inc. (Holding Co.) Report


Martha Stewart Living Omnimedia



Whole Foods Market

( WFMI),

Lincoln Electric Holdings

(LECO) - Get Lincoln Electric Holdings Inc. Report



(IR) - Get Ingersoll Rand Inc. Report


Illinois Tool Works

(ITW) - Get Illinois Tool Works Inc. Report


Becton, Dickinson

(BDX) - Get Becton Dickinson and Company Report


Dresser-Rand Group



American Science & Engineering



Thermo Electron

(TMO) - Get Thermo Fisher Scientific Inc Report


Grey Wolf

( GW),

Pioneer Drilling

( PDC),

General Cable




(ECA) - Get Encana Corporation Report


RF Micro Devices



Buffalo Wild Wings




(ENG) - Get ENGlobal Corporation Report


XM Satellite Radio

( XMSR) and

Smith & Wesson

( SWB).


Cramer was bearish on


(KR) - Get Kroger Company (The) Report



( CMGI) ,

New Century Financial

(NEW) - Get Puxin Ltd. Report



(INSP) - Get Inspire Medical Systems Inc. Report



(ORCL) - Get Oracle Corporation Report



( MXO),

Nam Tai Electronics




(AMR) - Get Alpha Metallurgical Resources Inc. Report


(AMZN) - Get Inc. Report



(C) - Get Citigroup Inc. Report


*For all you home-gamers, a 'mon-back opportunity means Cramer would back up the figurative truck and load up on a stock.

At the time of publication, Cramer was long UnitedHealth Group, EnCana, Yahoo! and Commerce Bancorp.

James J. Cramer is a director and co-founder of He contributes daily market commentary for's sites and serves as an adviser to the company's CEO. Outside contributing columnists for and, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for

ActionAlertsPLUS. While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by

clicking here. Listen to Cramer's RealMoney Radio show on your computer; just click

here. Watch Cramer on "Mad Money" at 6 p.m. ET weeknights on CNBC. Click

here to order Cramer's latest book, "Real Money: Sane Investing in an Insane World," click

here to get his second book, "You Got Screwed!" and click

here to order Cramer's autobiography, "Confessions of a Street Addict."